<DOC>
	<DOCNO>NCT00998725</DOCNO>
	<brief_summary>The purpose research study learn birth control pill call LoFemenal HIV+ HIV negative woman live Malawi . This pilot study determine effect antiretroviral therapy pharmacokinetics commonly use oral contraceptive HIV+ woman ; measure ovulation suppression woman take oral contraceptive pill antiretroviral therapy time . Nine woman enrol follow total 4 month .</brief_summary>
	<brief_title>Combined Oral Contraceptive ( COC ) Antiretroviral ( ARV ) Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Malawi</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Can provide informed consent Women age 2135 known HIV status If HIV negative must HIV test within last 3 month Intend stay Lilongwe region duration study Desire prevent pregnancy least next six month Desires use LoFemenal contraception Has know history infertility Has intact uterus least one ovary Has regular monthly menses define menses occur every 2135 day Has use another form systemic hormonal contraception within last six month . Has contraindication combine oral contraceptive LoFemenal include ; thrombophlebitis thromboembolic disorder ; cerebralvascular coronaryartery disease ( current history ) ; thrombogenic valvulopathies ; thrombogenic rhythm disorder ; major surgery prolong immobilization ; diabetes vascular involvement ; headache focal neurological symptom ; uncontrolled hypertension ; know suspect carcinoma breast personal history breast cancer ; carcinoma endometrium know suspected estrogen dependent neoplasia ; undiagnosed abnormal genital bleeding ; cholestatic jaundice pregnancy jaundice prior pill use ; hepatic adenoma carcinoma active lever disease , long liver function return normal ; know suspected pregnancy . Hemoglobin &lt; 10 mg/dL . Body mass index &lt; 18.6 kg/m^2 . Using drug know interfere cytochrome P450 system ( rifampicin , phenytoin , carbamezapine , among others ) In opinion PI study staff individual complete study Can adherent medication . Additional inclusion criterion 3 HIV+ woman antiretroviral therapy : Must antiretroviral therapy include nevirapine least three consecutive month immediately prior enrollment study Must report adherence medication medical visit Must willing use barrier backup method contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>